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Plexin C1, A Receptor for Semaphorin 7A, Inactivates
Cofilin and Is a Potential Tumor Suppressor for
Melanoma Progression
Glynis A. Scott1,2, Lindy A. McClelland1,2, Alex F. Fricke1,2 and Anne Fender1,2
Melanocytes are progenitor cells for melanoma, which arises through step-wise progression from dysplastic to
invasive, to metastatic tumor. Our previous data showed that semaphorin 7A (Sema7A), a protein involved in
axon guidance, stimulates melanocyte adhesion and dendricity through opposing actions of b1-integrin and
Plexin C1 receptors. We now show that Plexin C1 is diminished or absent in human melanoma cell lines;
analysis of tissue microarrays of nevi, melanoma, and metastatic melanoma showed a decrease in Plexin C1
expression in metastatic melanoma, and an inverse correlation of Plexin C1 expression with depth of invasion.
We examined the signaling intermediates of Sema7A and downstream targets of Plexin C1 in human
melanocytes. Sema7A activated mitogen-activated protein kinase and inactivated cofilin, an actin-binding
protein involved in cell migration. When Plexin C1 expression was silenced, Sema7A failed to phosphorylate
cofilin, indicating that cofilin is downstream of Plexin C1. Further, Lim kinase II, a protein that phosphorylates
cofilin, is upregulated by Sema7A in a Plexin C1-dependent manner. These data identify Plexin C1 as a potential
tumor suppressor protein in melanoma progression, and suggest that loss of Plexin C1 expression may promote
melanoma invasion and metastasis through loss of inhibitory signaling on cofilin activation.
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INTRODUCTION
Semaphorins are a large class of secreted and membrane-
anchored proteins that are important in neuronal pathfinding
and axon guidance in selected areas of the developing
nervous system (Pasterkamp and Verhaagen, 2006). Sema-
phorins are subdivided into eight subfamilies, two found in
invertebrates (classes 1 and 2), one in viruses (class 8), and
five in vertebrates (classes 3–7). Semaphorins stimulate
multiple signaling pathways, and all semaphorins have a
conserved semaphorin (sema) domain in the amino terminus,
which is also present in their receptors, the Plexins. The
prototypical semaphorin, semaphorin 3A/collapsin-1, causes
growth cone collapse of sensory neurons through remodeling
of cytoskeletal proteins, and the majority of semaphorins
described to date act as repellant signals to neurons (Giger
et al., 1998; Pasterkamp et al., 1998a, b, 1999). Although
their expression and function was originally described in the
brain and spinal cord, semaphorins are now known to be
widely expressed and have diverse functions. The protean
effects of semaphorins include regulation of blood vessel
development, modulation of the immune system, and drug
resistance (Yamada et al., 1997; Tamagnone and Comoglio,
2000; Ishida et al., 2003; Moretti et al., 2006). A role as tumor
suppressors and tumor promoters, in part through regulation of
tumor vessel formation, has also been described (Basile et al.,
2004, 2006; Bielenberg et al., 2004; Kessler et al., 2004).
Semaphorin 7A (Sema7A) is expressed at high levels in
lymphoid organs, odontoblasts, bone cells, the nervous
system of mice, and in human epidermal keratinocytes,
fibroblasts, and in endothelial cells of blood vessels of the
skin (Delorme et al., 2005; Maurin et al., 2005; Czopik et al.,
2006; Koh et al., 2006; Suzuki et al., 2007; Scott et al., 2008).
Sema7A binds to two distinct classes of receptors, b1-
integrins and Plexin C1 (Pasterkamp et al., 2003; Walzer
et al., 2005a, b). Integrins are transmembrane heterodimeric
proteins that link the extracellular matrix with the cyto-
skeleton and are critical for cell adhesion and migration
(Arnaout et al., 2007; Huveneers et al., 2007; Takagi, 2007).
The cytoplasmic domain of integrins couples to vinculin,
talin, and paxillin to form the focal adhesion complex, as well
as with kinases such as focal adhesion kinase (FAK), which is
phosphorylated upon integrin activation (Matsumoto et al.,
1995). Sema7A binds b1-integrins, resulting in neurite
extension, cytokine production, and migration in neurites,
monocytes, and bone cells, respectively (Pasterkamp et al.,
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2003; Delorme et al., 2005; Suzuki et al., 2007). We showed
that Sema7A stimulates melanocyte adhesion and dendrite
formation through b1-integrins, by demonstrating that block-
ing b1-integrin antibodies, and echistatin, a snake venom
that inhibits integrins, abrogated effects of Sema7A on
melanocyte adhesion and dendrite formation (Scott et al.,
2008). Therefore, integrin-mediated signaling appears to
be a common mechanism by which Sema7A effects are
controlled.
Plexins are a family of transmembrane receptors that bind
to secreted and membrane-bound semaphorins (Artigiani
et al., 1999; Tamagnone et al., 1999). Plexins were identified
through their homology to the extracellular domain of the
scatter factor receptors, and their cytoplasmic domains are
highly conserved. Some of the effects of Plexin signaling are
due to binding of guanosine triphosphate-binding proteins,
and to inhibition of integrin and cofilin activation (Swiercz
et al., 2004; Pasterkamp, 2005; Walzer et al., 2005a, b). Data
suggest that Plexin C1 is a receptor for Sema7A in some, but
not all cell types, suggesting additional ligands for Plexin C1
(Pasterkamp et al., 2003; Walzer et al., 2005a, b). There is
very limited information on the signaling pathways stimu-
lated by Plexin C1, however, in murine dendritic cells, Plexin
C1 signaling inactivates cofilin, and inhibits integrins,
resulting in decreased adhesion and migration (Walzer
et al., 2005a). We recently showed that human melanocytes
express abundant Plexin C1 at the message and protein level,
and that Plexin C1 is expressed in normal melanocytes in the
skin in vivo (Scott et al., 2008). The functional significance of
Plexin C1 in mediating Sema7A effects in melanocytes was
demonstrated through experiments in which silencing of
Plexin C1 resulted in enhanced adhesion and spreading in
response to Sema7A. Therefore, similar to murine dendritic
cells, Plexin C1 signaling abrogates melanocyte adhesion,
although the mechanisms have not been determined.
Melanoma is a deadly skin cancer that arises from
melanocytes, or melanocyte stem cells, through multiple
mechanisms. De novo expression of growth factors
and constitutive activation or upregulation of receptor
expression, stimulate pathways that result in melanoma
initiation and progression (Klein et al., 1991; Hamoen
et al., 2001; Haass et al., 2005; Hess et al., 2005).
Semaphorins regulate cell migration and motility in
virtually all cell types examined, so there is keen interest in
the possible role of semaphorins in tumor progression
(Artigiani et al., 1999; Kreuter et al., 2002; Bielenberg and
Klagsbrun, 2007; Hu et al., 2007). Investigation of the
potential role of semaphorins in melanoma progression is
limited, however, semaphorin 3F was identified as a tumor
suppressor of melanoma through effects on melanoma
proliferation (Bielenberg et al., 2004). The present study
shows that Plexin C1 expression is lost during melanoma
invasion and metastasis, and that cofilin, an actin-binding
protein involved in actin assembly, is a downstream target of
Plexin C1 signaling in melanocytes. We propose that Plexin
C1 is a previously undescribed tumor suppressor protein for
melanoma progression, and that loss of Plexin C1 promotes
melanoma progression through unopposed cofilin activation.
RESULTS
Plexin C1 expression is decreased at the protein and message
level in human melanoma cell lines
Total cell lysates of six human melanoma cell lines and
normal human melanocytes were blotted for Plexin C1
(Figure 1a). Plexin C1 is expressed in normal human
melanocytes, is absent from cell lines WM115 and C32,
and is decreased in WW165, YURIF, and YUSIK. YUMAC
show increased Plexin C1 protein expression compared with
normal melanocytes. Quantitative real-time PCR showed no
Plexin C1 PCR product in the two cell lines that completely
lacked Plexin C1 protein (Figure 1b; WM115 and C32). The
YUMAC and YURIF cell lines expressed Plexin C1 PCR
product at higher levels than melanocytes, despite lower
levels of Plexin C1 protein in one of these cell lines (YURIF)
compared with melanocytes. The WW165 melanoma cell
line, which expressed lower Plexin C1 protein, also
expressed less Plexin C1 mRNA. De novo production of
growth factors are implicated in melanoma tumor progres-
sion, therefore, we determined cell-surface expression of
Sema7A by FACs analysis of stained cells. Positive controls
consisted of normal human fibroblasts, which we have
shown express Sema7A (Scott et al., 2008). None of the six
human melanoma cell lines expressed detectable Sema7A
(data not shown).
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Figure 1. (a) Plexin C1 protein expression is decreased in human melanoma.
Total cell lysates of melanocytes (MC) and six human melanoma cell lines
were resolved on 7.5% SDS–PAGE and blotted with antibodies to Plexin C1.
The lower part of the membrane was blotted for b-actin. Melanocytes express
large amounts of Plexin C1. Plexin C1 is completely absent in cell lines
WM115 and C32, is decreased in WM165, YURIF, and YUSIK, and is slightly
increased in YUMAC. Results are representative of three separate
experiments. (b) Plexin C1 message is decreased or absent in 3 of 6 human
melanoma cell lines. Message RNA was reverse transcribed from melanocytes
and six human melanoma cell lines. Quantitative real-time PCR of each
sample was performed in triplicate against a standard curve of Plexin C1 PCR
product to arrive at a quantitative Plexin C1 level. Three of the six cell lines
either had no Plexin mRNA (C32 and WM115) or decreased Plexin C1 mRNA
(WW165) compared with melanocytes. Plexin C1 message was increased
compared with melanocytes in two cell lines (YURIF and YUMAC). Results
are the averaged amount of Plexin C1 message (±SD) of three separate
experiments.
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Plexin C1 expression correlates with melanoma progression
Tissue microarrays were constructed from 26 cases of benign
nevi, 27 cases of melanoma primary to the skin, and 24 cases
of metastatic melanoma. For metastatic melanoma, 11 of 24
cases were metastatic to lymph nodes, 5 of 24 were
metastatic to skin, and 8 of 24 cases were metastatic to
organs including gastrointestinal system, lung, and bone. The
percentage of cases from each group exhibiting no staining
(0–1.5 intensity score, IS), moderate staining (1.6–2.5 IS) and
strong staining (2.6–3.0 IS) is presented in Figure 2. A total of
66% of metastatic melanomas did not express Plexin C1,
whereas all nevi showed either moderate or strong expression
of Plexin C1. Expression of Plexin C1 was significantly
different in nevi compared with metastatic melanoma, and
between primary melanoma and metastatic melanoma
(Po0.001). Nevi expressed more Plexin C1 than primary
melanoma, and these differences were also statistically
significant (Po0.05). Representative photographs of nevi,
melanoma, and metastatic melanoma stained for Plexin C1
are shown in Figure 3a–d.
The average IS of the 26 nevi was 2.76 (±0.34 SD); 69%
of nevi showed strong expression of Plexin C1 (IS between
2.6 and 3.0), 27% of nevi showed moderately strong Plexin
C1 expression (IS between 1.6 and 2.5), and no cases were
negative for Plexin C1 (IS between 0 and 1.5). Figure 3a
shows representative cores of two cases of nevi stained for
Plexin C1. Strong and diffuse membranous expression of
Plexin C1 is observed. The lowest IS for a nevus was 2.3.
The expression of Plexin C1 by melanoma primary to the
skin was more heterogeneous (Figure 3b). The average IS for
all cases (n¼27) was 2.38 (±0.84 SD), which was
significantly different from nevi (0.05), and ranged from 0
to 3. A total of 57% of cases showed strong staining, 25%
showed moderately strong staining, and 17% showed no
staining. Of note, a case of melanoma arising within a nevus
showed strong staining of the nevic cells, but weak staining of
the melanoma (Figure 3c). The depth of invasion of
melanoma is a major prognostic indicator (Balch et al.,
1980; Patrick et al., 2007). When Plexin C1 expression was
analyzed in melanomas of different depths of invasion, a
trend of diminished Plexin C1 expression with increasing
depth of invasion was observed (Figure 3b). Melanomas with
a depth o1mm (n¼9), which are considered thin melano-
mas with a near 100% 5-year survival, had an IS score for
Plexin C1 of 3 (±0.10 SD). Melanomas with a depth of
invasion between 1.01 and 2.0mm (n¼8) had an IS score of
2.5 (±0.53 SD). Melanomas with a depth of invasion
between 2.01 and 4.0mm (n¼6) had an IS score of 2
(±0.51 SD) and melanomas with a depth of invasion of
44mm (n¼ 4), which are advanced tumors with a 50%
5-year survival rate, had an IS of 1.32 (±0.47 SD). Student’s
t-test showed that Plexin C1 expression was significantly
different (Po0.001) between thin melanomas (depth of
invasiono1mm) and deeply invasive tumors (depth44mm).
A striking decrease in Plexin C1 expression was observed
in metastatic melanoma (Figure 3d). The average IS for Plexin
C1 in all cases of metastatic melanoma (n¼24) was 1.0
(±0.97), which was significantly different from nevi
(Po0.001) and melanoma primary to the skin (Po0.001). A
total of 67% of metastatic melanomas did not stain at all for
Plexin C1 and only 20% of cases showed moderately strong
staining. Two of the five cases that showed strong staining (IS
2.6–3.0) for Plexin C1 were tumors metastatic to skin and
bone.
Sema7A stimulates cofilin inactivation, and activates FAK and
MAP kinase, in human melanocytes
To examine potential mechanisms by which loss of Plexin C1
leads to melanoma progression, we analyzed the signaling
pathways stimulated by Sema7A in normal human melano-
cytes and the downstream targets of Plexin C1 signaling. The
activity of cofilin is controlled through phosphorylation of the
protein at Ser-33, which results in its inactivation (Moriyama
et al., 1996). Treatment of melanocytes with Sema7A
stimulated the rapid phosphorylation of cofilin, as determined
by western blotting with antibodies against cofilin phos-
phorylated on Ser-33 (Figure 4a). Phosphorylation of cofilin
occurred within 5minutes of treatment with Sema7A and
began to diminish 30minutes later. We have demonstrated
previously that Sema7A stimulates melanocyte adhesion and
dendrite formation through b1-integrin receptors. To deter-
mine if Sema7A stimulates integrin signaling, we examined
the effect of Sema7A on the activation of the non-receptor
protein tyrosine kinase FAK. FAK is rapidly phosphorylated
upon integrin receptor binding, resulting in propagation of
integrin signals (Richardson and Parsons, 1995; Hehlgans
et al., 2007). Sema7A stimulated the rapid phosphorylation of
FAK in melanocytes, indicative of b1-integrin signaling
(Figure 4a). A dose–response analysis showed that detectable
Plexin C1 expression in nevi, melanoma and metastatic
melanoma
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Figure 2. Loss of Plexin C1 is correlated with progression of primary
melanoma to metastatic melanoma. Compiled data of Plexin C1 intensity
scores (IS) of TMAs of nevi, melanoma primary to the skin, and metastatic
melanoma. The percentage of cases of nevi, melanoma, and metastatic
melanoma with no Plexin C1 staining, moderately strong staining, and strong
staining is shown. A total of 66% of metastatic melanomas (pale gray bars) did
not express Plexin C1, whereas all nevi (hatched bars) showed either
moderate or strong expression of Plexin C1. Expression of Plexin C1 was
significantly different in nevi compared with metastatic melanoma, and
between primary melanoma (black bars) and metastatic melanoma
(Po0.001). Nevi expressed more Plexin C1 than primary melanoma, and
these differences were statistically significant (Po0.05).
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cofilin and FAK phosphorylation occurred at 10 ngml1
Sema7A, and peaked at 50 ngml1 (Figure 4b). Sema7A
activates mitogen-activated protein (MAP) kinase in neurons
(Pasterkamp et al., 2003; Huang et al., 2007; Li et al., 2007;
Yee et al., 2008). To determine if Sema7A activates MAP
kinase in melanocytes, cells were treated with Sema7A (doses
ranging from 1 to 50 ngml1) for 5minutes, and total cell
lysates were blotted for phosphorylated extracellular-regu-
lated kinases (Erks) 1 and 2 (Figure 4c). Sema7A stimulated
the rapid phosphorylation of Erk1/Erk2 at a dose of
10 ngml1, which peaked at a dose of 25 ngml1, which
was inhibited by the selective MAP kinase kinase inhibitor
PD 98059 (Figure 4d). To determine if Sema7A-dependent
phosphorylation of FAK and cofilin requires Erk1/Erk2
activation, melanocytes were treated with Sema7A
(50 ngml1 for 5minutes) in the presence or absence of PD
98059. Pretreatment of melanocytes with PD 98059 for
2 hours did not block phosphorylation of FAK or cofilin in
response to Sema7A, suggesting that cofilin and FAK
phosphorylation are not downstream of Erk1/Erk2 activation
(data not shown).
Plexin C1 signaling stimulates cofilin phosphorylation/
inactivation in melanocytes
To determine the relationship between Plexin C1 signaling
and cofilin phosphorylation, Plexin C1 was silenced in
melanocytes using siRNAs, and silenced cells were treated
with Sema7A (50 ngml1) for 5 and 15minutes. Partial
(475%) silencing of Plexin C1 was achieved in the samples
from the 5-minute treatment condition; complete silencing
was achieved in the 15-minute treatment samples (Figure 5a).
Phosphorylation of cofilin in response to Sema7A directly
correlated with levels of Plexin C1 expression. At the 5-
minute time point, in which residual Plexin C1 was present,
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Figure 3. Plexin C1 is lost during melanoma progression in vivo. (a) Benign nevi strongly express Plexin C1. Two representative cases of benign nevi from TMA
stained for Plexin C1 are shown. One core from each case, with a high power inset, is shown, along with the assigned intensity score (IS). The nevic cells in
virtually all nevi showed moderate to strong expression of Plexin C1. Mag¼0.4mm; inset Mag¼ 200mm. (b) Primary melanomas show Plexin C1 expression
intermediate between nevi and metastatic melanoma. Four representative cases of melanomas stained for Plexin C1 from TMA are shown. One core from each
case, with a high-power inset, along with the assigned intensity score (IS) is shown. Of note, one case showed melanoma arising within a nevus. In this case,
strong expression of Plexin C1 within the nevic cells (*) is present, juxtaposed with melanoma cells with weaker Plexin C1 expression (arrows). Mag¼ 0.4mm;
inset Mag¼ 200mm. (c) Plexin C1 expression decreases with increasing depth of invasion. When cases were separated into groups of different depths of
invasion, a clear trend of decreasing Plexin C1 expression with increasing depth of invasion is present. Thin melanomas (0.1–1mm) had a significantly higher IS
for Plexin C1 compared with melanomas 4mm or thicker (IS of 3 and 1.33, respectively, Po0.001). (d) Metastatic melanomas express low levels of Plexin C1.
Four representative cases of metastatic melanoma from TMA stained for Plexin C1 are shown. One core from each case, with a high-power inset, along with the
assigned intensity score (IS) is shown. The vast majority of metastatic melanomas did not express Plexin C1. Mag¼ 0.4mm; inset Mag¼ 200mm.
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phosphorylation of cofilin in response to Sema7A was
diminished, but not absent. At the 15-minute point, in which
Plexin C1 levels were fully silenced, phosphorylation of
cofilin in response to Sema7A was completely abrogated. In
contrast with cofilin phosphorylation, silencing of Plexin C1
expression had no effect on Erk1/Erk2 phosphorylation in
response to Sema7A (Figure 5b).
Cofilin is a direct downstream target of LIM kinases
(LIMK), which phosphorylate cofilin on Ser-33. There are two
isoforms of LIMK; LIMKI is expressed in neural cells, whereas
LIMKII is expressed more widely (Bernard, 2007; Scott and
Olson, 2007). To determine which isoform of LIMK is
expressed in human melanocytes and our panel of melanoma
cell lines, total cell lysates were blotted for LIMK1 and LIMKII
(Figure 5c). LIMKII, but not LIMKI, was expressed by
melanocytes, and by 3 of 5 melanoma cell lines. Of interest,
the two cell lines that completely lack LIMKII expression
(WM115 and C32) also lack Plexin C1, and levels of LIMKII
roughly correlate with Plexin C1 expression in melanoma cell
lines (Figure 1a).
To determine if Plexin C1 regulates LIMKII expression,
Plexin C1 was silenced in melanocytes, and 24 hours later
silenced cells, and cells transfected with scrambled siRNA,
were treated with Sema7A (50 ngml1). Controls consisted of
cells treated with supernatants of COS-1 cells that do not
stable express Sema7A (Figure 5d). Twenty-four hours after
the second treatment with Sema7A (72 hours after silencing),
cells were lysed. Lysates were resolved on 6% SDS–PAGE,
transferred to nitrocellulose membranes, and the membrane
was cut and blotted for Plexin C1, LIMKII, and b-actin.
Melanocytes transfected with scrambled siRNA (which have
normal Plexin C1 levels) and treated with Sema7A, showed a
marked increased LIMKII expression, compared with cells
treated with COS-1 supernatants. The increase in LIMKII in
response to Sema7A was abrogated in cells in which Plexin
C1 was silenced, confirming that Plexin C1 is involved in the
effect of Sema7A on LIMKII expression. These data indicate
that LIMKII expression is regulated, at least in part, by
Sema7A-dependent Plexin C1 signaling, suggesting that the
Plexin C1–LIMKII–cofilin pathway is tightly controlled in
melanocytes.
DISCUSSION
We recently showed that Sema7A is expressed in the skin,
where it controls the dendricity and adhesion of human
melanocytes through the opposing actions of Sema7A-
dependent b1-integrin and Plexin C1 signaling (Scott et al.,
2008). An interesting observation that emerged from that
initial study was that silencing of Plexin C1 enhanced the
effect of Sema7A on melanocyte adhesion and dendricity,
suggesting that Plexin C1 signals downstream to targets that
inhibit actin assembly or turnover. Gain or loss of receptor
expression, or de novo expression of growth factors,
contributes to melanoma initiation and progression (Herlyn
et al., 1988; Easty and Bennett, 2000; Meier et al., 2003;
Haass et al., 2005; Kwong et al., 2007). In six human
melanoma cell lines, Plexin C1 protein expression was
completely absent in two, was decreased in three, and was
slightly increased in one. Levels of Plexin C1 mRNA generally
correlated with protein expression, however, the YURIF
melanoma cell line, which expressed less Plexin C1 protein
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Figure 4. Sema7A actuates FAK and Erk1/Erk2, and inhibits cofilin. (a)
Sema7A stimulates the phosphorylation of FAK and cofilin in human
melanocytes. Melanocytes were placed in basal medium (MCDB-153) for
8 hours and were treated with recombinant Sema7A (100 ngml1) for the
indicated time points; controls were treated with vehicle. Total cell lysates
were resolved on 10% SDS–PAGE and blotted for phosphorylated focal
adhesion kinase (FAK) and phosphorylated cofilin. Sema7A stimulated the
rapid (within 5minutes) phosphorylation of FAK, indicative of integrin
activation. Levels of inactive (phosphorylated) cofilin were also rapidly
increased in melanocytes upon Sema7A treatment, which peaked at 15min.
Results are representative of three separate experiments performed on pooled
cultures of human melanocytes. (b) A dose–response analysis of FAK and
cofilin phosphorylation in response to Sema7A was performed. Melanocytes
were placed in basal medium (MCDB-153) for 8 hours and were treated with
recombinant Sema7A at doses ranging from 1 to 100 ngml1, for 5min.
Controls were treated with vehicle. Total cell lysates were resolved on 10%
SDS–PAGE and blotted for phosphorylated FAK and phosphorylated cofilin.
Maximal FAK and cofilin phosphorylation was observed at 50 ngml1
(arrow), and in the case of FAK, occurred at concentrations of Sema7A as low
as 1 ngml1. Cofilin phosphorylation was first detected at a dose of
10 ngml1 of Sema7A. Results are representative of two separate experiments
performed on pooled cultures of human melanocytes. (c, d) Sema7A
stimulates MAP kinase activation in melanocytes. Melanocytes were placed
in basal medium (MCDB-153) for 8 hours and were treated for 5min with
recombinant Sema7A at doses ranging from 1 to 50ngml1; controls were
treated with vehicle. Total cell lysates were resolved on 10% SDS–PAGE and
blotted for phosphorylated Erk1/Erk2; the blot was stripped and reblotted for
total Erk1/Erk2. A dose-dependent increase in P-Erk1/Erk2 was observed in
response to Sema7A, with a peak response seen at a dose of 25 ngml1
(arrow). Results are representative of two separate experiments. (d) The
specificity of MAP kinase activation was tested in melanocytes by the
inclusion of the selective p42/44 MAP kinase inhibitor PD 98059 (10mM) in
cells treated with Sema7A (25 ngml1) for 5minutes. Cell lyates resolved
on SDS–PAGE and blotted for P-Erk1/Erk2 are shown. The blot was stripped
and reblotted for total Erk1/Erk2. As expected, Sema7A stimulated
phosphorylation of Erk1/Erk2 within 5minutes of treatment. Cells treated with
PD 98059 for 1 hour before treatment with Sema7A showed no induction of
Erk1/Erk2 phosphorylation. Results are representative of two separate
experiments.
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than melanocytes, had increased levels of Plexin C1 message.
The reason for this is unclear, but may reflect a longer mRNA
half-life, or increased degradation of the protein. The
mechanism by which Plexin C1 is lost in melanoma remains
to be determined. Loss of heterozygosity contributes to Apaf-
1 deletion, a gene linked to Plexin C1 on chromosome 12,
that is also lost during melanoma progression (Soengas et al.,
2001). The complete absence of Plexin C1 message in 2 of 6
melanoma cell lines suggests that gene deletion may be
involved in loss of Plexin C1. We are currently examining
genomic DNA from metastatic and primary melanomas to
determine if Plexin C1 loss is due to deletion of part or the
entire gene.
We examined the expression of Plexin C1 by immunohis-
tochemical staining of TMA of benign nevi, melanoma
primary to the skin, and metastatic melanoma. Tissue
microarrays allow analysis of multiple samples on the same
slide that are uniformly stained (Simon et al., 2004). Our data
indicate a striking loss of Plexin C1 expression in metastatic
melanoma, and an inverse correlation between Plexin C1
expression and tumor invasiveness in primary melanomas.
Nevic cells in virtually all subjects showed strong homo-
genous expression of Plexin C1. In contrast, the majority of
metastatic melanomas showed weak or no staining for Plexin
C1. The expression of Plexin C1 in primary melanoma was
intermediate between nevi and metastatic tumors, and Plexin
C1 expression was progressively lost in melanomas of
increasing depth. Very deep melanomas (44mm) showed
an average IS of 1.3, compared with thin melanomas
(o1mm) that showed an average IS of 3. Particularly
informative was the juxtaposition of a benign nevus and
melanoma, in which strong expression of Plexin C1 was
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Figure 5. Plexin C1 signaling regulates cofilin activation and LIMKII expression. (a, b) Silencing of Plexin C1 abrogates cofilin phosphorylation/inactivation, but
has no effect on MAP kinase activation. Melanocytes were plated onto four 60mm dishes, and two dishes were transfected with siRNAs to Plexin C1 (Si) and two
dishes were transfected with scrambled siRNAs (Sc). At 48 hours later, cells were placed in basal medium for 8 hours and then treated for 5 or 15minutes with
Sema7A (50 ngml1). Total cell lysates were resolved on 7.5% SDS–PAGE. The top of the membrane was blotted for Plexin C1, and the bottom was blotted for
phospho-cofilin. (a) Phosphorylation of cofilin, in response to Sema7A, correlated with levels of Plexin C1 expression; at the 5minute time point, in which Plexin
C1 was silenced450%, there was a450% reduction in phosphorylated cofilin. In the 15minutes sample, in which total silencing of Plexin C1 was achieved,
there was no detectable phosphorylation of cofilin. The different degree of silencing of Plexin C1 likely reflects differences in silencing efficiency between the
dishes. Results are representative of three separate experiments. (b) Melanocytes were transfected with siRNAs to Plexin C1 (Si) or scrambled siRNAs (Sc) as
described above and treated for 5minutes with Sema7A (25 ngml1). Total cell lysates were resolved on 7.5% SDS–PAGE. The top of the membrane was blotted
for Plexin C1, and the bottom was blotted for phospho-Erk1/2. Knockdown of Plexin C1 did not affect phosphorylation of Erk1/Erk2 in response to Sema7A.
Results are representative of three separate experiments. (c) Human melanocytes and melanoma cells express LIMKII. Lysates (40mg) of human melanocytes
(MC), WM115, WW165, C32, YURIF, YUMAC, and YUSIK were resolved on 10% SDS–PAGE and blotted with antibodies that recognize LIMKI or LIMKII. None
of the cells express LIMKI. Melanocytes, and 4 of 6 melanoma cell lines, express LIMK II. Interestingly, the expression of LIMKII correlates with Plexin C1
expression (Figure 1a). Results are representative of two separate experiments. (d) Plexin C1 signaling regulates LIMKII expression. Melanocytes were plated onto
four 60mm dishes, and two dishes were transfected with siRNAs to Plexin C1 (Si) and two dishes were transfected with scrambled siRNAs (Sc). At 24 and
48hours after silencing, cells were treated with either Sema7A (50 ngml1) or COS-1 supernatants from nontransfected cells (‘‘C’’). At 24 hours following the
second treatment (72 hours after silencing), cells were lysed and resolved on 6% SDS–PAGE. The top of the membrane was blotted for Plexin C1, the middle was
blotted for LIMKII, and the bottom was blotted for b-actin. Melanocytes treated with Sema7A show a marked increased LIMKII expression, compared with cells
treated with COS-1 supernatants. Silencing of Plexin C1 abrogated the effect of Sema7A on LIMKII expression. Representative results of three separate
experiments are shown.
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evident in the nevic cells and was absent in the melanoma
cells (Figure 3b). In toto, these data support a role for Plexin
C1 as a tumor suppressor protein for melanoma progression.
Because expression of Plexin C1 in benign nevi and super-
ficially invasive melanoma (o1mm depth of invasion) was
essentially the same, loss of Plexin C1 is likely to promote
tumor progression (invasion and metastasis) rather than tumor
initiation. Studies in which Plexin C1 expression in melano-
mas are correlated with matched metastatic tumors, are
currently being performed to determine if loss of Plexin C1
expression in primary tumors is correlated with metastatic
disease in individual patients. If so, Plexin C1 expression has
the potential to be useful as a prognostic indicator for
melanoma metastasis.
Cofilin activation is strongly linked to tumor progression,
although the relationship between cofilin activation and
tumor progression is complex (Paavilainen et al., 2004;
Huang et al., 2006). Loss of cofilin expression in metastatic
tumor cell lines is associated with decreased cell turning and
chemotactic sensitivity to epidermal growth factor (Sidani
et al., 2007) and the cofilin activation pathway is a major
determinant of breast cancer metastasis (Wang et al., 2007).
Although there are abundant data to suggest a role for cofilin
activation in carcinogenesis, data on the role of cofilin and
melanoma progression is more limited. Knockdown of cofilin
and actin depolymerizing factor in B16F1 melanoma cells
inhibited cell migration primarily through diminished actin
filament depolymerization rates (Hotulainen et al., 2005). In
K1735 murine melanoma cells, expression of wild-type
(nonphosphorylatable) cofilin increased melanoma invasion
and migration (Dang et al., 2006). Although the mechanisms
by which loss of Plexin C1 promotes melanoma progression
are likely multifactorial, our data indicate a potential link
between loss of Plexin C1 and cofilin activation in
melanoma.
Sema7A stimulated the rapid phosphorylation of cofilin
and FAK at low doses (10 ngml1) in human melanocytes.
Phosphorylation of FAK, which occurs upon integrin activa-
tion, is consistent with our prior data showing that Sema7A-
dependent melanocyte adhesion occurs through the engage-
ment of b1-integrins (Scott et al., 2008). MAP kinase was also
activated by Sema7A in normal human melanocytes, and was
unaffected by Plexin C1 silencing. It is likely that MAP kinase
activation is secondary to Sema7A-dependent integrin
activation, as has been reported in neural cells, bone cells,
and monocytes (Pasterkamp et al., 2003; Delorme et al.,
2005; Suzuki et al., 2007). To address whether Plexin C1
regulates cofilin phosphorylation, we silenced Plexin C1 in
human melanocytes, and examined the effect of Sema7A on
cofilin phosphorylation. When Plexin C1 was silenced,
Sema7A-dependent cofilin phosphorylation was lost or
attenuated, indicating that Plexin C1 regulates cofilin
phosphorylation. The LIMK family of proteins consists of
two members, LIMKI, and LIMKII, which phosphorylate
cofilin at Ser-33 (Bernard, 2007; Scott and Olson, 2007).
LIMKI is primarily expressed in the central nervous system
whereas LIMKII is widely expressed (Scott and Olson, 2007).
Normal melanocytes, and 4 of 6 melanoma cell lines
examined, expressed LIMKII, but not LIMKI, making LIMKII
a likely downstream target of Plexin C1 signaling in
melanocytic cells. Examination of cofilin regulation in
melanocytes expressing kinase dead mutants of LIMKII will
be needed to address the role of LIMKII in Plexin C1-
dependent cofilin regulation. Of interest was the precise
correlation between levels LIMKII and Plexin C1 expression:
melanoma cell lines lacking Plexin C1 (C32 and WM115)
also lacked LIMKII, and levels of LIMKII protein closely
paralleled Plexin C1 levels. Because treatment of melano-
cytes with Sema7A upregulated the expression of LIMKII, and
because silencing of Plexin C1 blocked Sema7A-dependent
LIMKII upregulation, we propose that Plexin C1 signaling
stimulates either the synthesis or stability of LIMKII. There-
fore, loss of Plexin C1 by melanoma cells may result in
additional changes in cytoskeletal regulatory proteins, such
as LIMKII, which are important for cell motility. It will be of
interest to examine potential coordinated loss of Plexin C1
and LIMKII in melanoma TMAs.
In summary, we have demonstrated that Plexin C1, a
receptor for Sema7A, is decreased or lost during melanoma
progression in vivo, and that Plexin C1 signaling in normal
human melanocytes results in phosphorylation and inactiva-
tion of cofilin. These data are the first to define the signaling
intermediates of Sema7A in human melanocytes, and point
to a role for Plexin C1 as a previously undescribed tumor
suppressor protein for melanoma progression, potentially
through loss of inhibition of cofilin activation. Future
studies examining the role of Plexin C1 in melanoma
migration, metastasis, and interaction with integrin receptor
signaling, are being planned to define the effect of loss of
Plexin C1 in critical determinants melanoma progression and
metastasis.
MATERIALS AND METHODS
Reagents
Rabbit polyclonal antibodies to b-actin, goat polyclonal antibodies
to Plexin C1, and rabbit polyclonal antibodies to LIMKI and LIMKII
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA);
rabbit polyclonal antibodies to cofilin phosphorylated on Ser-33,
rabbit polyclonal antibodies to phospho-p44/42 MAP kinase, and
mouse MAbs to p42 MAP kinase were purchased from Cell Signaling
Technology (Danvers, MA), mouse MAbs to FAK phosphorylated on
Y397 were purchased from Chemicon International (Temecula, CA).
Horseradish peroxidase-conjugated goat anti-rabbit and goat anti-
mouse antibodies were purchased from Sigma Co. (St. Louis, MO).
FITC-conjugated mouse anti-human Sema7A (CDw108) and mouse
IgM conjugated to FITC for flow cytometry were purchased from
Serotec (Kidlington, Oxford, UK). Full range rainbow molecular
weight markers were purchased from Amersham Life Sciences
(Arlington Heights, IL). Silencing RNAs (siRNA) to human Plexin C1,
Silencer Negative Control no. 1 siRNA, and lipofectamine were
purchased from Ambion (Austin, TX). Sema7A, in frame with human
Fc fragment, in pcDNA3 vector was a generous gift from Dr Ruslan
Medzhitov (Section of Immunobiology, Yale University, New
Haven, CT) and has been described previously (Czopik et al.,
2006). The selective p42/44 MAP kinase inhibitor PD 98059 was
purchased from Sigma Co.
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Cells and cell culture
Neonatal foreskins were obtained according to the University of
Rochester Research Subjects Review Board guidelines and were the
source of cultured human melanocytes. Human melanocytes were
cultured in MCDB 153 supplemented with 0.5% fetal bovine serum
(FBS), bovine pituitary extract (15 mgml1), phorbol ester (10 nM),
basic fibroblast growth factor (1 ngml1), insulin (5mgml1), and
hydrocortisone (500 ngml1). All supplements were purchased from
Sigma Co., except FBS, which was purchased from Mediatech
(Manassas, VA). The following human melanoma cell lines were
purchased from the Yale University Cell Core Facility: WW165,
YURIF, YUSIK, YUMAC, and were maintained in Opti-MEM þ 5%
FBS, except WW165 which was maintained in Opti-MEM þ 5% FBS
and IBMX 0.1mM. The C32 and WM115 human melanoma cell lines
were obtained from ATCC (Manassas, VA) and were maintained in
Eagle minimal essential media þ 10% FBS and 1mM sodium
pyruvate. The WW165, WM115, and C32 cell lines were derived
from melanomas primary to the skin; the other cell lines were
derived from metastatic melanoma.
Purification of Fc-tagged Sema7A
Fc-tagged Sema7A was isolated from culture supernatant of stable
transfectants of COS-1 cells expressing Fc-Sema7A, on HiTrap
protein A HP columns (General Electric Healthcare, St. Giles, UK) as
per manufacturer’s instructions. Eluent was resolved on a 7.5%
SDS–PAGE and blotted for Sema7A to verify its identity as previously
described (Scott et al., 2008). Coomassie-stained gels showed a
single band corresponding to the molecular weight of Sema7A at a
protein concentration of 1mgml1.
Construction, staining, and analysis of tissue microarrays
The project received IRB exemption from the Human Subjects
Review Board at the University of Rochester: category 4 (45 CRF
46.101): secondary use of preexisting data. A total of 26 cases of
benign nevi, 27 cases of melanoma primary to the skin, and 24 cases
of metastatic melanoma were chosen from formalin-fixed, paraffin-
embedded archival material from Strong Memorial Department of
Pathology. One of the authors (GS) diagnosed each case during
clinical duties as Director of Dermatopathology at Strong Memorial
Hospital, Rochester, NY. The slides from each case were reexamined
and three representative areas from each slide were chosen. Three
1mm cores corresponding to these areas were removed from the
paraffin block and placed in a recipient block. All benign nevi were
dermal nevi with a minimal junctional component, primary
melanomas had depths of o1mm (n¼ 9), between 1.01 and
2.0mm (n¼ 8), between 2.01 and 4.0mm (n¼ 6), and 44mm
(n¼ 4). For metastatic melanoma, 11 of 24 cases were metastatic
to lymph nodes, 5 of 24 were metastatic to skin, and 8 of 24 cases
were metastatic to organs including gastrointestinal system, lung,
and bone.
Staining of TMA for Plexin C1
Sections were deparaffinized through graded series of alcohol,
rehydrated in water, and endogenous peroxidase was quenched by
incubation in 3% H2O2 for 3min 2 . Nonspecific staining was
blocked by incubation in nonprotein blocking solution (Dako,
Carpenteria, CA) for 15min at room temperature. Antigen retrieval
was performed by incubating the slides in Target Retrieval
Buffer (Dako) at 98 1C for 15minutes. Slides were incubated
with polyclonal antibodies against Plexin C1 in antibody diluent
(1/100; Dako) for 1 h at room temperature. Sections were then
incubated with biotin-conjugated rabbit anti-goat antibodies for
30minutes at room temperature followed by streptavidin horse-
radish-peroxidase (Vector Laboratories, Burlingame, CA) for 20min-
utes. The reaction was developed with amino-ethyl carbizol and the
slides were counterstained in Mayer’s hematoxylin. Negative
controls consisted of goat IgG (Sigma Co.) instead of the primary
antibody.
Analysis of TMAs
The intensity of staining of each 1mm core was rated on a scale of
0–3, with 0, negative; 1, weak; 2, moderate, and 3, strong. For all
cases, when staining was present, it was diffused, with all nevi cells
or melanoma cells expressing uniform staining for Plexin C1. Each
core was examined under a light microscope by one of the authors
(GS) and separately scored, and the staining intensity of the cores
averaged to arrive at an IS. Cores with o50% of designated tissue
present were disregarded. Cases with an average IS score of 0–1.5
were considered negative; those with an IS score between 1.6 and
2.5 were considered moderately positive, and those with an IS score
of 2.6–3 were considered strongly positive.
Statistical evaluation of data
Data were summarized in terms of their mean and standard
deviation. Tissue expression of Plexin C1 was analyzed using
Fisher’s exact test to determine statistically significant difference in
expression between nevi, primary melanoma, metastatic melanoma,
and in melanomas of different Breslow depths (0.1–1, 1.01–2.0,
2.1–4, and 44.0mm). A P-value of o0.05 was considered
significant.
Western blotting and flow cytometry
For western blotting, cells were lysed in radioimmunoprecipitation
assay buffer (150mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS,
50mM Tris-HCl) with protease inhibitors (Boehringer Mannheim
GmbH, Mannheim, Germany) and phosphatase inhibitors (GBio-
sciences, St. Louis, MO) and protein was quantified using BSA as
standard (Bio-Rad Laboratories, Hercules, CA). Visualization of the
immunoreactive proteins was accomplished with an enhanced
chemiluminescence reaction (Pierce Chemical, Rockford, IL). For
analysis of cell surface Sema7A expression in melanoma cell lines by
flow cytometry, cells were placed in suspension in phosphate-
buffered saline/1% BSA and stained with FITC-conjugated antibodies
against Sema7A for 30minutes at room temperature. Negative
controls consisted of cells incubated with FITC-conjugated IgM.
Positive controls consisted of normal human fibroblasts. After
washing in phosphate-buffered saline, cells were resuspended in
0.5% formalin in phosphate-buffered saline/1% BSA and analyzed
using a FACS Caliber Machine (Becton Dickinson) at the flow
cytometry core facility at the University of Rochester.
Quantitative real-time PCR
Total RNA was isolated using the RNeasy Mini Kit (QIAGEN,
Valencia, CA) according to manufacturer’s instructions. Reverse
transcription was performed using 0.75mg of total RNA with
SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA). PCR
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was performed using iQ SYBR Green Supermix (Bio-Rad Labora-
tories) on the Applied Biosystems ABI prism 7700 sequence-
detection system (Bio-Rad iCycler). Primers used for amplification
of Plexin C1 were: forward: 50-AACCATTGCACTGCAACC-30;
reverse: 50-GATTCCATCTTCAAGAATCACG-30. The conditions
were: 95 1C, 3minutes (1 cycle); 95 1C 15 seconds, 54.5 1C,
30 seconds, 72 1C, 40 seconds (40 cycles). Primers used for
amplification of b-actin were: forward: 50-CACGCACGATTTCCC
GCTCGG-30; reverse: 50-CAGGCTGTGCTATCCTGTAC-30. The con-
ditions were 95 1C, 3minutes (1 cycle); 95 1C 15 seconds, 54.5 1C,
30 seconds, 72 1C, 40 seconds (40 cycles). The PCR product was
resolved on 1% agarose gels, sequenced, and verified. Quantifica-
tion of PCR product was determined by analyzing a standard curve
of known amounts of Plexin C1 PCR product to unknown samples.
Samples were then normalized to b-actin.
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